Eckert & Ziegler SE · ISIN: DE0005659700 · EQS - Company News

Changes in the Executive Board and Supervisory Board

Berlin, 3 December 2024. The Supervisory Board of Eckert & Ziegler SE has appointed Dr. Gunnar Mann (57) as a new member of the Executive Board, effective 1 January 2025. He will assume operational responsibility for the Medical segment. Dr. Mann who holds a doctorate in physics, joined Eckert & Ziegler in 1998 and initially started as head of development. He then served as managing director of various subsidiaries of Eckert & Ziegler SE and was appointed to the Group Executive Commi...

XETR:EUZ Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News Eckert & Ziegler SE

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (12)
Short Selling (DE) (3)
Short Selling (UK) (0)
03 December 2024 02:29PM
Changes in the Executive Board and Supervisory Board
DE0005659700
Berlin, 3 December 2024. The Supervisory Board of Eckert & Ziegler SE has appointed Dr. Gunnar Mann (57) as a new member of the Executive Board, effective 1 January 2025. He will assume operational responsibility for the Medical segment. Dr. Mann who holds a doctorate in physics, joined Eckert & Ziegler in 1998 and initially started as head...
Eckert & Ziegler SE
About the publication
02 December 2024 09:00AM
Eckert & Ziegler Begins Production of Actinium-225, Paving the Way for GMP-Grade Supply
DE0005659700
Berlin, 02 December 2024. Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler) today celebrates the successful start of Actinium-225 (Ac-225) production, addressing the global shortage of this critical radionuclide. This milestone marks a major success of the common project with the Nuclear Physics Institute of the Czech Academy of Sciences...
Eckert & Ziegler SE
About the publication
27 November 2024 09:00AM
Eckert & Ziegler Achieves European Approval for Theralugand® - Lutetium-177 Chloride (n.c.a)
DE0005659700
Berlin, 27 November 2024. Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler) today received approval of its proprietary non-carrier added Lutetium-177 chloride, Theralugand®, by the European Commission (EC). This enables the use of the radiopharmaceutical medicinal product Theralugand® in routine clinical applications throughout the Europ...
Eckert & Ziegler SE
About the publication
22 November 2024 03:27PM
Eckert & Ziegler raises its forecast for the current financial year once again
DE0005659700
Eckert & Ziegler raises its forecast for the current financial year once again.Forecast for 2024: Sales of around EUR 290 million (raised) EBIT before special items of around EUR 60 million (raised) Berlin, 22 November 2024 Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) is once again raising its annual forecast for the current financial ...
Eckert & Ziegler SE
About the publication
14 November 2024 07:45AM
Eckert & Ziegler Continues on Growth Path with Strong 9-Month Results in 2024
DE0005659700
Berlin, November 14, 2024. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) increased its sales by 17% year-on-year to € 215.5 million in the first nine months of 2024. Recurring EBIT from continuing operations (adjusted EBIT) rose by 24% to € 46.7 million. Net income (from continuing and discontinued operations) grew by 15% and reached € 23.4 m...
Eckert & Ziegler SE
About the publication
13 November 2024 08:54AM
Eckert & Ziegler and Telix Pharmaceuticals Enter into a Collaboration and Licence Agreement for Actinium-225
DE0005659700
Berlin, 13 November 2024. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) today signed a collaboration and licence agreement with the Australian-headquartered Telix Pharmaceuticals Limited (Telix) for the use of EZAG’s cyclotron-based technology to produce Ac-225. The contract entitles Eckert & Ziegler to milestone payments from Telix total...
Eckert & Ziegler SE
About the publication
15 October 2024 04:33PM
Eckert & Ziegler Again Increases Sales and Earnings in the First Nine Months Compared to Previous Year
DE0005659700
3rd quarter of 2024: Sales of EUR 70.1 million (previous year: EUR 65.9 million) EBIT before special items of EUR 15.5 million (previous year: EUR 15.1 million) Net income of EUR 5.3 million (previous year: EUR 9.4 million)  First 9 months of 2024:  Sales of EUR 215.5 million (previous year: EUR 183.9 million) EBIT before special items of EUR ...
Eckert & Ziegler SE
About the publication
08 October 2024 08:00AM
Eckert & Ziegler and GlyTherix Sign Agreement for Lutetium-177 Supply
DE0005659700
Berlin, Germany and Sydney, Australia - 08. October 2024  - Eckert & Ziegler (ISIN DE0005659700, SDAX) and GlyTherix Ltd (GlyTherix), an Australian targeted radiotherapy company specialising in developing antibody radiopharmaceuticals for solid tumors, today announced a new global clinical supply agreement. Eckert & Ziegler will provide its...
Eckert & Ziegler SE
About the publication
02 October 2024 11:43AM
Spin-off of Pentixapharm AG Registered with the Commercial Register
DE0005659700
Berlin, 2 October 2024. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) announces that the spin-off resolution approved at the Annual General Meeting on 26 June 2024 was entered in the commercial register of the Charlottenburg (Berlin) District Court today. With the entry in the commercial register of Eckert & Ziegler SE, the spin-off of Pe...
Eckert & Ziegler SE
About the publication
20 August 2024 05:00PM
Eckert & Ziegler opens new facilities for radiopharmaceutical plant engineering in Dresden
DE0005659700
Berlin, 20.08.2024. In the presence of the Saxon State Ministers Martin Dulig and Thomas Schmidt as well as the Mayor of Dresden Dirk Hilbert, the medical technology company Eckert & Ziegler today inaugurated its new 1,700 square meter facilities in Dresden with around 200 guests. The Dresden-Rossendorf site produces and delivers high-tech syst...
Eckert & Ziegler SE
About the publication
13 August 2024 09:00AM
Eckert & Ziegler becomes European contract manufacturer for Telix's innovative Phase III ProstACT GLOBAL study
DE0005659700
Berlin, August 13, 2024 - Eckert & Ziegler and Telix Pharmaceuticals Limited (Telix) today announced the signing of a significant multi-year agreement under which Eckert & Ziegler will serve as the European contract manufacturing organization (CMO) for Telix's ProstACT GLOBAL Phase III study. The contract covers the supply of the entire Eur...
Eckert & Ziegler SE
About the publication
09 August 2024 07:45AM
Eckert & Ziegler Continues Sales and Earnings Growth in the First Half of 2024
DE0005659700
2nd Quarter 2024: Sales: € 77.8 Mio. million (PY: € 60.1 million) EBIT before special items: € 17.5 million (PY: € 12.0 million) Net income: € 9.5 million (PY: € 6.2 million) 1st Half Year 2024: Sales: € 145,4 million (PY: € 118.0 million) EBIT before special items: € 32.5 million (PY: € 22.6 million) Net income: € 18.0 million (PY: € 10.9 mi...
Eckert & Ziegler SE
About the publication
05 August 2024 03:45PM
Eckert & Ziegler extends GalliaPharm® availability to the entire European Economic Area
DE0005659700
August 5, 2024 - Berlin - Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler) has received approval from the European Commission (EC) for its Ge-68/Ga-68 radionuclide generator GalliaPharm®. The generator was first launched in 2014 and is today approved in 17 European countries and many other key international markets. With the EC approval...
Eckert & Ziegler SE
About the publication
16 July 2024 02:26PM
Eckert & Ziegler Again Increases Sales and Earnings Compared to Previous Year. Profit Forecast Raised for 2024.
DE0005659700
2nd quarter of 2024: Sales of EUR 77.8 million (previous year: EUR 60.1 million) EBIT before special items of EUR 17.5 million (previous year: EUR 12.0 million) Net income of EUR 9.5 million (previous year: EUR 6.2 million) 1st half of 2024:  Sales of EUR 145.4 million (previous year: EUR 118.0 million) EBIT before special items of EUR 32.5 mi...
Eckert & Ziegler SE
About the publication
26 June 2024 04:27PM
Annual General Meeting of Eckert & Ziegler SE Approves Split-Off of Pentixapharm AG
DE0005659700
Berlin, June 26, 2024. The Annual General Meeting of Eckert & Ziegler SE (ISIN DE0005659700) today resolved to split-off Pentixapharm AG from Eckert & Ziegler SE and to distribute a dividend of EUR 0.05 per share for the 2023 financial year. As in the previous year, the Annual General Meeting was held as an in-person event at Eckert & ...
Eckert & Ziegler SE
About the publication
25 June 2024 12:00PM
Eckert & Ziegler Subsidiary Pentixapharm Receives Encouraging FDA Feedback to Initiate Phase III Trial with PentixaFor as Radiopharmaceutical Diagnostic in Primary Aldosteronism
DE0005659700
Würzburg/Berlin, Germany, 25 June 2024. Pentixapharm AG, a radiopharmaceutical development company wholly owned by Eckert & Ziegler SE, today announced that it has received encouraging feedback from the U.S. Food and Drug Administration (FDA) following a recent Type C meeting with the Agency to directly proceed into a pivotal phase III registra...
Eckert & Ziegler SE
About the publication
25 June 2024 12:00PM
Eckert & Ziegler Subsidiary Pentixapharm Receives Encouraging FDA Feedback to Initiate Phase III Trial with PentixaFor as Radiopharmaceutical Diagnostic in Primary Aldosteronism
DE0005659700
Würzburg/Berlin, Germany, 25 June 2024. Pentixapharm AG, a radiopharmaceutical development company wholly owned by Eckert & Ziegler SE, today announced that it has received encouraging feedback from the U.S. Food and Drug Administration (FDA) following a recent Type C meeting with the Agency to directly proceed into a pivotal phase III registra...
Eckert & Ziegler SE
About the publication
19 June 2024 09:00AM
Eckert & Ziegler and UJF Open State-of-the-Art Actinium-225 Production Facility
DE0005659700
June 19, 2024 – Berlin, Germany and Řež, Czech Republic – Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler), in collaboration with the Nuclear Physics Institute of the Czech Academy of Sciences (Ústav jaderné fyziky, “UJF”), announces the grand opening of a pioneering Actinium-225 (Ac-225) production facility. This milestone, celebrated ...
Eckert & Ziegler SE
About the publication
31 May 2024 09:00AM
Eckert & Ziegler Hosts Second Radionuclide Theranostics Forum in Boston, MA
DE0005659700
BOSTON, Mass., May 31, 2024 – Eckert & Ziegler reports about the successful completion of the 2nd annual Boston Radionuclide Theranostics Forum, reaffirming its pivotal role in the field of radiopharmaceuticals. Building on the momentum of last year's inaugural event, the Forum once again brought together leading experts, potential and existing...
Eckert & Ziegler SE
About the publication
24 May 2024 09:00AM
Eckert & Ziegler receives “Best Managed Companies Award”
DE0005659700
Berlin, 24 May 2024. Eckert & Ziegler SE (ISIN DE0005659700) was honored with the “Best Managed Companies Award” at an award ceremony in Frankfurt am Main on May 23, 2024. With this award, Deloitte Private, UBS, Frankfurter Allgemeine Zeitung and the Federation of German Industries (Bundesverband der Deutschen Industrie e.V.) recognize outstand...
Eckert & Ziegler SE
About the publication
14 May 2024 07:50AM
Eckert & Ziegler with significant increase in sales (+17%) and adjusted EBIT (+41%) in Q1. Forecast 2024 confirmed.
DE0005659700
1st Quarter 2024: Sales of € 67.6 million (previous year: € 57.9 million) EBIT before special items of € 15.0 million (previous year: € 10.6 million) Net income € 8.5 million (previous year: € 4.7 million)  Forecast FY 2024: Sales of just under € 265 Mio. (confirmed) EBIT before special items of around € 50 million (confirmed) Berlin, 14 May 2...
Eckert & Ziegler SE
About the publication
22 April 2024 02:49PM
Q1 with Significant Increase in Sales and Earnings Compared to Previous year. 2024 Annual Forecast Confirmed.
DE0005659700
1st Quarter 2024: Sales of EUR 67.6 million (previous year: EUR 57.9 million) EBIT before special items of EUR 15.0 million (previous year: EUR 10.7 million) Net income for the year of EUR 8.5 million (previous year: EUR 4.7 million) Forecast FY 2024: Sales of just under 265 million EUR (confirmed) EBIT before special items of around EUR 50 mi...
Eckert & Ziegler SE
About the publication
22 April 2024 02:49PM
Q1 with Significant Increase in Sales and Earnings Compared to Previous year. 2024 Annual Forecast Confirmed.
DE0005659700
1st Quarter 2024: Sales of EUR 67.6 million (previous year: EUR 57.9 million) EBIT before special items of EUR 15.0 million (previous year: EUR 10.7 million) Net income for the year of EUR 8.5 million (previous year: EUR 4.7 million) Forecast FY 2024: Sales of just under 265 million EUR (confirmed) EBIT before special items of around EUR 50 mi...
Eckert & Ziegler SE
About the publication
22 March 2024 07:45AM
Eckert & Ziegler Continues on Growth Path after Successful Financial Year 2023
DE0005659700
Berlin, March 22, 2024 - Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) generated sales of € 246.1 million in the 2023 financial year. Compared to the previous year, sales increased by € 23.8 million or 11%. EBIT from continuing operations before special items reached € 46.9 million. Net profit for the year amounted to € 26.3 million correspon...
Eckert & Ziegler SE
About the publication
21 March 2024 10:00AM
Eckert & Ziegler Receives MDR Certification for Prostate Seeds, Paving the Way for Long-term Supply
DE0005659700
Berlin, Germany – 21 March 2024 – Eckert & Ziegler BEBIG GmbH, subsidiary of Eckert & Ziegler SE with focus on brachytherapy solutions for the treatment of prostate cancer as well as eye and brain tumors, obtained the MDR certificate for its proprietary prostate seeds from DEKRA Certification B.V. as one of the first companies in its market...
Eckert & Ziegler SE
About the publication
19 March 2024 07:46PM
Eckert & Ziegler Reduces Dividend to Finance Future Investments. Earnings Growth Expected for 2024.
DE0005659700
Berlin, 19 March 2024 – The Supervisory Board and Executive Board of Eckert & Ziegler (ISIN DE0005659700, TecDAX) today decided to propose to the Annual General Meeting a reduced dividend of € 0.05 per share entitled to a dividend. The liquidity thus remaining in the company will be used to finance new high-return projects in the continuously g...
Eckert & Ziegler SE
About the publication
19 March 2024 10:53AM
Eckert & Ziegler Completes Change of Legal Form to SE
DE0005659700
Berlin, 19.03.2024. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) today completed its change of legal form to a Societas Europaea (SE) with entry in the company's commercial register and will in future operate as Eckert & Ziegler SE. Eckert & Ziegler SE has a dualistic management system consisting of a management...
Eckert & Ziegler Strahlen- und Medizintechnik AG
About the publication
28 February 2024 10:00AM
Eckert & Ziegler Extends Ga-68 Activities in Japan
DE0005659700
Berlin, Germany – 28 February 2024 – Eckert & Ziegler (ISIN DE0005659700, SDAX) expands its activities on Gallium-68 (Ga-68) labeled diagnostics in Japan together with Novartis Pharma K.K. (Japan). For this purpose, a clinical trial was notified with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA), stating Eckert & Ziegler’s ...
Eckert & Ziegler Strahlen- und Medizintechnik AG
About the publication
31 January 2024 02:00PM
Eckert & Ziegler to Supply Nucleus Radiopharma with Therapeutic Radioisotopes Ac-225 and Lu-177
DE0005659700
Eckert & Ziegler's supply of Lu-177 and Ac-225 enables Nucleus Radiopharma entering a new era in cancer care Berlin, Germany and Rochester, MN, USA – January 31, 2024 – Eckert & Ziegler (ISIN DE0005659700, SDAX) and Nucleus Radiopharma (Nucleus) signed extensive supply agreements for major therapeutic radioisotopes. Eckert & Ziegler wi...
Eckert & Ziegler Strahlen- und Medizintechnik AG
About the publication
23 January 2024 08:00AM
Eckert & Ziegler and Full-Life Technologies Sign Actinium-225 Supply Agreement for Next Generation Radiopharmaceuticals
DE0005659700
Berlin, Germany and Gembloux, Belgium – 23 January 2024 – Eckert & Ziegler (ISIN DE0005659700, SDAX) and Full-Life Technologies (Full-Life), a clinical stage, fully integrated global radiotherapeutics company today announced they have entered into an agreement for the supply of Actinium-225 (Ac-225). The agreement provides Full-Life with access...
Eckert & Ziegler Strahlen- und Medizintechnik AG
About the publication
08 January 2024 10:00AM
Eckert & Ziegler and ARTBIO Announce Manufacturing and Supply Partnership for Lead-212 Conjugates
DE0005659700
Berlin, Germany and Cambridge, Mass., – 8 January 2024 – Eckert & Ziegler (ISIN DE0005659700, SDAX) and ARTBIO, Inc. (ARTBIO), a clinical-stage biotechnology company specializing in the development of a new class of alpha radioligand therapies (ARTs), have entered into a strategic manufacturing and supply agreement. Under the collaboration Ecke...
Eckert & Ziegler Strahlen- und Medizintechnik AG
About the publication
22 November 2023 04:02PM
First CNS Lymphoma Patient Dosed in Phase I/II PTT101 Study with Yttrium (90Y) Anditixafortide (PentixaTher)
DE0005659700
Berlin/Würzburg, 22 November 2023. Pentixapharm AG, a developer of innovative radiopharmaceuticals owned by Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) today has announced that a first patient has been treated in a dose-finding clinical phase I/II study with Yttrium (90Y) anditixafortide (PentixaTher) at the University ...
Eckert & Ziegler Strahlen- und Medizintechnik AG
About the publication
21 November 2023 03:26PM
Personnel Changes in the Management. Changes in the Executive Board and Supervisory Board.
DE0005659700
Berlin, November 21, 2023. Dr. Hakim Bouterfa, Executive Board member of Eckert & Ziegler AG and responsible for clinical development, will leave the Executive Board of Eckert & Ziegler AG at the end of the year and in future will concentrate exclusively on his tasks as Executive Board member of the Eckert & Ziegler subsidiary Pentixaph...
Eckert & Ziegler Strahlen- und Medizintechnik AG
About the publication
14 November 2023 12:04PM
Eckert & Ziegler Establishes German-Chinese Joint Venture with DC Pharma for the Production of Radioisotopes
DE0005659700
Berlin, 14.11.2023. Eckert & Ziegler (ISIN DE0005659700) strengthens its competitive position in the growth market of China and today signed a 50:50 joint venture agreement with the Chinese pharmaceutical company DongCheng Pharma (DC Pharma). Eckert & Ziegler will benefit from the cooperation between the two companies above all at its prod...
Eckert & Ziegler Strahlen- und Medizintechnik AG
About the publication
14 November 2023 07:45AM
Eckert & Ziegler with Significant Sales Growth in the First Nine Months of 2023
DE0005659700
Berlin, 14 November 2023. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, SDAX) achieved sales of € 183.9 million in the first nine months of 2023 (previous year: € 165.8 million) and consolidated net income of € 20.3 million (previous year: € 21.7 million). Adjusted for currency losses of € 3.3 million, the nine-month resu...
Eckert & Ziegler Strahlen- und Medizintechnik AG
About the publication
23 October 2023 09:00AM
Eckert & Ziegler to Supply Ablaze Pharmaceuticals with Lutetium-177 for Clinical Trials
DE0005659700
Berlin, Germany and Shanghai, China – 23 October 2023 – Eckert & Ziegler (ISIN DE0005659700, SDAX) and Ablaze Pharmaceuticals (Ablaze) signed a comprehensive supply agreement for non-carrier added Lutetium-177 (n.c.a. 177Lu). Eckert & Ziegler will serve as the supplier for Ablaze’s clinical trial and research activities utilizing Lutetium-1...
Eckert & Ziegler Strahlen- und Medizintechnik AG
About the publication
20 October 2023 03:40PM
Focus on Core Competencies and Split-Off of Pentixapharm AG
DE0005659700
Berlin, 20 October 2023. Berlin, xx.10.2023. The Executive Board of Eckert & Ziegler AG (ISIN DE0005659700, SDAX) resolved at its meeting today, with the approval of the Supervisory Board, the strategy and investment priorities for the coming years. In this context the Supervisory Board of Eckert & Ziegler AG  has given its approval to the ...
Eckert & Ziegler Strahlen- und Medizintechnik AG
About the publication
20 October 2023 03:18PM
Eckert & Ziegler Focuses on Core Competence and Prepares Split-Off of Clinical Assets
DE0005659700
Berlin, 20 October 2023. The Supervisory Board of Eckert & Ziegler AG (ISIN DE0005659700, SDAX) today has given its approval to the Executive Board to examine and prepare a split-off of up to 100 percent of the shares in the Pentixapharm AG (PTX). In accordance with IFRS 5, the Executive Board will report PTX as a discontinued operation in the ...
Eckert & Ziegler Strahlen- und Medizintechnik AG
About the publication
17 October 2023 04:57PM
Eckert & Ziegler Achieves Double-Digit Growth in Q3 versus Previous Year. Significant Jump in Sales also in First 9 Months, Earnings still Burdened by Special Items Compared to Same Period Last Year.
DE0005659700
Q3 2023: sales of 65.9 million EUR (previous year: 57.2 million EUR) profit of 9.4 million EUR (previous year: 7.9 million EUR) First 9 months of 2023: sales of 183.9 million EUR (previous year: 164.0 million EUR) profit of 20.3 million EUR (previous year: 23.3 million EUR) Forecast 2023: sales of just under 230 million EUR (confirmed) profit...
Eckert & Ziegler Strahlen- und Medizintechnik AG
About the publication
10 October 2023 03:00PM
Eckert & Ziegler and PharmaLogic Sign Reservation Agreement for Supply of Therapeutic Radioisotope Actinium-225
DE0005659700
Berlin, Germany and BOCA RATON, FL, USA – 10 October 2023 – Eckert & Ziegler (ISIN DE0005659700, SDAX) and PharmaLogic Holdings Corp. (“PharmaLogic”) have signed a reservation agreement for the supply of the therapeutic radioisotope Actinium-225 (Ac-225). Under the terms of the agreement, PharmaLogic will have access to Eckert & Ziegler's h...
Eckert & Ziegler Strahlen- und Medizintechnik AG
About the publication
28 September 2023 10:00AM
Eckert & Ziegler Receives Award for Professional Training
DE0005659700
Berlin, September 28, 2023. Eckert & Ziegler AG has been awarded the Pankow 2023 Training Prize for outstanding training quality. The award was presented yesterday at a celebration event by Berlin-Pankow District Mayor Dr. Cordelia Koch. The jury justified the award with the great commitment to professional training and the special training co...
Eckert & Ziegler Strahlen- und Medizintechnik AG
About the publication
25 September 2023 11:17PM
Eckert & Ziegler Signs Strategically Important Agreement for the Supply of Lutetium-177 with POINT Biopharma
DE0005659700
Berlin, 25 September 2023. Eckert & Ziegler AG (ISIN DE0005659700, SDAX) today signed an agreement with POINT Biopharma Global Inc. ("POINT", NASDAQ: PNT) for the supply of carrier-free lutetium-177 (n.c.a.177Lu). The agreement has a term of ten years with a total sales volume of more than € 100 million. The lutetium-177 supply is conditional ...
Eckert & Ziegler Strahlen- und Medizintechnik AG
About the publication
13 September 2023 03:00PM
Eckert & Ziegler collaborates with RefleXion Medical and Telix Pharmaceuticals to Expand Treatment Options for Prostate Cancer Patients
DE0005659700
Collaboration will develop and market Satellite Hot Labs for radiolabeling of BioGuides Berlin, Germany – 13 September 2023 – Eckert & Ziegler (ISIN DE0005659700, TecDAX) today announced they have entered into a comprehensive collaboration agreement with RefleXion Medical, Inc. (RefleXion) and Telix Pharmaceuticals Limited (ASX:TLX, Telix) to ...
Eckert & Ziegler Strahlen- und Medizintechnik AG
About the publication
10 August 2023 07:45AM
Eckert & Ziegler Continues Positive Sales Development in the First Half of 2023
DE0005659700
Berlin, 10 August 2023. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) increased its sales by 10% to € 118.0 million in the first half of 2023. At € 10.9 million or € 0.52 per share, net income was € 3.5 million or 25% lower than in the same period last year. Currency effects in particular reduced the result by aro...
Eckert & Ziegler Strahlen- und Medizintechnik AG
About the publication
21 July 2023 03:21PM
Eckert & Ziegler again achieves sales growth compared to the previous year and confirms its forecast for 2023. Decline in earnings compared to same period last year due to extraordinary items.
DE0005659700
First half of 2023: sales of 118.0 million EUR (previous year: 106.8 million EUR) profit of 10.9 million EUR (previous year: 15.4 million EUR) Forecast 2023: sales of just under 230 million EUR (confirmed) profit of around EUR 25 million (confirmed) Berlin, July 21, 2023. According to preliminary calculations, Eckert & Ziegler AG (ISIN DE00...
Eckert & Ziegler Strahlen- und Medizintechnik AG
About the publication
21 July 2023 03:21PM
Eckert & Ziegler again achieves sales growth compared to the previous year and confirms its forecast for 2023. Decline in earnings compared to same period last year due to extraordinary items.
DE0005659700
First half of 2023: sales of 118.0 million EUR (previous year: 106.8 million EUR) profit of 10.9 million EUR (previous year: 15.4 million EUR) Forecast 2023: sales of just under 230 million EUR (confirmed) profit of around EUR 25 million (confirmed) Berlin, July 21, 2023. According to preliminary calculations, Eckert & Ziegler AG (ISIN DE00...
Eckert & Ziegler Strahlen- und Medizintechnik AG
About the publication
08 June 2023 11:31AM
PentixaPharm Receives BfArM-Clearance for its Therapeutic to conduct a Clinical Trial in Lymphoma
DE0005659700
Würzburg, Bavaria, 8 June 2023. PentixaPharm GmbH, a developer of innovative radiopharmaceuticals fully owned by Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700; TecDax) has received the approval from the German Federal Institute for Drugs and Medical Devices (BfArM) to start PTT101, its open-label dose escalation study to e...
Eckert & Ziegler Strahlen- und Medizintechnik AG
About the publication
08 June 2023 11:31AM
Eckert & Ziegler: PentixaPharm Receives BfArM-Clearance for its Therapeutic to conduct a Clinical Trial in Lymphoma
DE0005659700
Würzburg, Bavaria, 8 June 2023. PentixaPharm GmbH, a developer of innovative radiopharmaceuticals fully owned by Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700; TecDax) has received the approval from the German Federal Institute for Drugs and Medical Devices (BfArM) to start PTT101, its open-label dose escalation study to e...
Eckert & Ziegler Strahlen- und Medizintechnik AG
About the publication
More Eckert & Ziegler SE related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 12 27th March 2024 Eckert, Dr. Andreas DD
Short Seller (DE) 3 17th November 2022 JPMorgan Asset Management (UK) Ltd SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN